<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283387</url>
  </required_header>
  <id_info>
    <org_study_id>2147-05</org_study_id>
    <secondary_id>5R01DK073354-04</secondary_id>
    <nct_id>NCT00283387</nct_id>
  </id_info>
  <brief_title>Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria</brief_title>
  <official_title>Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orphan Europe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy and safety of betaine in reducing urine
      oxalate excretion of Type 1 Primary Hyperoxaluria (PHI) patients.

      Hypothesis:

      Betaine will effectively reduce urine oxalate excretion in Primary Hyperoxaluria Type I
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our prior genotyping results have shown an association between the G170R allele and the
      clinical response to VB6. Patients homozygous for this change show a complete response and
      heterozygous patients a partial response. Since VB6 is a safe and completely effective
      treatment for patients homozygous for G170R, we will not study betaine in this group.
      Instead, 20 participants older than 6 years of age who are G170R compound heterozygous,
      non-G170R missense or truncating sequence change homozygous or heterozygous, will be selected
      for enrollment. Participants in whom VB6 provides a partial reduction in urine oxalate
      excretion (compound heterozygotes for the G170R mutation) will be maintained on a stable dose
      of VB6 (8 mg/kg/d) for two months before and throughout betaine treatment. Those who have
      demonstrated no response to VB6 will receive betaine alone.

      Participants will be randomized to receive either betaine or placebo for the first 2 month
      arm of the study. Following 2 months of treatment and 2 months of washout, each participant
      will cross over to the other arm of the study. The other arm will consist of the participant
      being on 2 months of treatment of whatever they were not taking in the first arm (betaine vs.
      placebo). Neither the study staff nor the participant will know whether the participant is
      taking betaine for the first or second arm of the study, or the placebo for the first or
      second arm of the study. Only the pharmacy will know this.

      Prior to the study, a complete history and physical examination, and baseline laboratory
      studies pertinent to the routine care of primary hyperoxaluria patients will be performed
      (Complete Blood Count (CBC) with differential, chemistry group, electrolytes, plasma oxalate
      and creatinine clearance, urinary supersaturation). All women capable of reproduction will
      receive a pregnancy test prior to enrollment.

      Participant will complete two 24-hour urine collections for calcium oxalate super-saturation
      (includes 24-hour urine oxalate excretion) at baseline, inclusive of creatinine determination
      for assessment of completeness. They will then begin Cystadane anhydrous solution (12
      grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of
      age and older, in two divided doses). These doses of betaine have been shown to effectively
      treat pediatric patients with VB6-resistant homocystinuria and reverse Nonalcoholic
      Steatohepatitis (NASH) in adult patients, so we expect they will achieve sufficient
      intra-hepatocyte levels to have an effect in PHI.

      A sample of each 24-hour urine will be stored frozen (-80ÂºC) to allow determination of
      indicators of oxidant stress, should urinary oxalate fall.

      If effective, betaine could represent a new and safe treatment option for a subset of PHI
      patients, particularly those with either partially VB6 responsive or VB6 refractory
      hyperoxaluria, or those with adverse effects such as peripheral neuropathy from large doses
      of VB6. We do not anticipate any adverse medication effects specific to primary
      hyperoxaluria. However, as an extra safeguard for children with PHI, ten subjects older than
      15 years of age will be tested first and if the agent is well tolerated in PHI patients,
      pediatric subjects older than 6 years of age will then be recruited for participation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Oxalate Excretion</measure>
    <time_frame>baseline, 2 months, 6 months</time_frame>
    <description>The patients were randomly assigned oral betaine or placebo for 2 months, followed by a 2 month washout. Each patient then received the alternate study medication for 2 months.
Urinary Oxalate Excretion was measured by oxalate oxidase. Two 24 hour urine collections were obtained at baseline, and during the eighth week of each study period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>Betaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral lactose placebo, in two doses daily, for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects were randomly assigned to receive oral lactose placebo, in two doses daily, for 2 months. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaine</intervention_name>
    <description>Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.</description>
    <arm_group_label>Betaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cystadane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects received oral lactose placebo, in two doses daily, for 2 months.</description>
    <arm_group_label>Betaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lactose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A definitive diagnosis of Type 1 Primary Hyperoxaluria (PHI) as confirmed by hepatic
             angiotensinogen (AGT) deficiency, biochemical criteria (marked hyperoxaluria and
             hyperglycolic aciduria) or mutation analysis (having a known PHI mutation)

          2. Alanine-glyoxylate aminotransferase (AGXT) genotype known

          3. Hyperoxaluria not fully corrected by 3 months of continuous Vitamin B6 (VB6) at doses
             of 8 mg/kg/d or more

          4. Males or females, 6-70 years of age, inclusive

          5. Preserved renal function, as defined by measured glomerular filtration rate (GFR) &gt; 30
             ml/min/1.73 m^2

          6. Sexually active female patients of childbearing potential must practice adequate
             contraception during the treatment period and for 6 months after discontinuation of
             therapy. A pregnancy test obtained at entry prior to the initiation of treatment must
             be negative. Female patients must not be breast-feeding. Sexually active male patients
             must practice acceptable methods of contraception during the treatment period and for
             6 months after discontinuation of therapy.

          7. Written informed consent for participation in this study.

        Exclusion Criteria:

          1. Patients who are fully VB6 responsive (i.e., G170R homozygotes).

          2. Prior recipients of liver transplantation performed for correction of AGT deficiency.

          3. Pregnancy or breastfeeding

          4. Unwillingness of patient and/or partner to use contraception during treatment.

          5. Malignant disease (other than non-melanoma skin cancer) in the previous two years.

          6. Markedly reduced renal function (Stage IV Chronic Kidney Disease or measured or
             estimated GFR &lt; 30 ml/min/1.73 m^2)

          7. Allergy to betaine or related compounds

          8. History of papilledema or increased intracranial pressure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla G Monico, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic Hyperoxaluria Center, Rochester MN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hyperoxaluria Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mayoclinic.org/nephrology-rst/hyperoxaluriacenter.html</url>
    <description>Mayo Clinic Hyperoxaluria Center home page</description>
  </link>
  <link>
    <url>http://www.mayoclinic.org/hyperoxaluria/</url>
    <description>Mayo Clinic Hyperoxaluria Center (disease web page)</description>
  </link>
  <link>
    <url>http://www.ohf.org</url>
    <description>Oxalosis and Hyperoxaluria Foundation</description>
  </link>
  <reference>
    <citation>Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001 Sep;96(9):2711-7.</citation>
    <PMID>11569700</PMID>
  </reference>
  <reference>
    <citation>Adamzik M, Schmermund A, Reed JE, Adamzik S, Behrenbeck T, Sheedy PF 2nd. Comparison of two different software systems for electron-beam CT-derived quantification of coronary calcification. Invest Radiol. 1999 Dec;34(12):767-73.</citation>
    <PMID>10587873</PMID>
  </reference>
  <reference>
    <citation>ARCHER HE, DORMER AE, SCOWEN EF, WATTS RW. Primary hyperoxaluria. Lancet. 1957 Aug 17;273(6990):320-2.</citation>
    <PMID>13464052</PMID>
  </reference>
  <reference>
    <citation>Barak AJ, Beckenhauer HC, Badakhsh S, Tuma DJ. The effect of betaine in reversing alcoholic steatosis. Alcohol Clin Exp Res. 1997 Sep;21(6):1100-2.</citation>
    <PMID>9309323</PMID>
  </reference>
  <reference>
    <citation>Bourot S, Sire O, Trautwetter A, TouzÃ© T, Wu LF, Blanco C, Bernard T. Glycine betaine-assisted protein folding in a lysA mutant of Escherichia coli. J Biol Chem. 2000 Jan 14;275(2):1050-6.</citation>
    <PMID>10625645</PMID>
  </reference>
  <reference>
    <citation>Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, Deries N. Epidemiology of primary hyperoxaluria type 1. SociÃ©tÃ© de NÃ©phrologie and the SociÃ©tÃ© de NÃ©phrologie PÃ©diatrique. Nephrol Dial Transplant. 1995;10 Suppl 8:3-7.</citation>
    <PMID>8592622</PMID>
  </reference>
  <reference>
    <citation>Danpure CJ and Rumsby G. Enzymology and molecular genetics of primary hyperoxaluria type 1. Consequences for clinical management. In: Calcium Oxalate in Biological Systems, edited by Khan SR. Boca Raton, FL: CRC Press, 1995, p. 189-205.</citation>
  </reference>
  <reference>
    <citation>Diamant S, Eliahu N, Rosenthal D, Goloubinoff P. Chemical chaperones regulate molecular chaperones in vitro and in cells under combined salt and heat stresses. J Biol Chem. 2001 Oct 26;276(43):39586-91. Epub 2001 Aug 21.</citation>
    <PMID>11517217</PMID>
  </reference>
  <reference>
    <citation>Diamant S, Rosenthal D, Azem A, Eliahu N, Ben-Zvi AP, Goloubinoff P. Dicarboxylic amino acids and glycine-betaine regulate chaperone-mediated protein-disaggregation under stress. Mol Microbiol. 2003 Jul;49(2):401-10.</citation>
    <PMID>12828638</PMID>
  </reference>
  <reference>
    <citation>Levine DZ, Nash LA, Chan T, Dubrovskis AH. Proximal bicarbonate reabsorption during Ringer and albumin infusions in the rat. J Clin Invest. 1976 Jun;57(6):1490-7.</citation>
    <PMID>932191</PMID>
  </reference>
  <reference>
    <citation>Lumb MJ, Birdsey GM, Danpure CJ. Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro. Biochem J. 2003 Aug 15;374(Pt 1):79-87.</citation>
    <PMID>12737622</PMID>
  </reference>
  <reference>
    <citation>Lumb MJ, Danpure CJ. Functional synergism between the most common polymorphism in human alanine:glyoxylate aminotransferase and four of the most common disease-causing mutations. J Biol Chem. 2000 Nov 17;275(46):36415-22.</citation>
    <PMID>10960483</PMID>
  </reference>
  <reference>
    <citation>Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 2005 May;67(5):1704-9.</citation>
    <PMID>15840016</PMID>
  </reference>
  <reference>
    <citation>Purdue PE, Takada Y, Danpure CJ. Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol. 1990 Dec;111(6 Pt 1):2341-51.</citation>
    <PMID>1703535</PMID>
  </reference>
  <reference>
    <citation>Rantanen I, Nicander I, Jutila K, Ollmar S, Tenovuo J, SÃ¶derling E. Betaine reduces the irritating effect of sodium lauryl sulfate on human oral mucosa in vivo. Acta Odontol Scand. 2002 Oct;60(5):306-10.</citation>
    <PMID>12418722</PMID>
  </reference>
  <reference>
    <citation>Santana A, Salido E, Torres A, Shapiro LJ. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7277-82. Epub 2003 May 30.</citation>
    <PMID>12777626</PMID>
  </reference>
  <reference>
    <citation>Schwahn BC, Hafner D, Hohlfeld T, Balkenhol N, Laryea MD, Wendel U. Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. Br J Clin Pharmacol. 2003 Jan;55(1):6-13.</citation>
    <PMID>12534635</PMID>
  </reference>
  <reference>
    <citation>Voziyan PA, Fisher MT. Polyols induce ATP-independent folding of GroEL-bound bacterial glutamine synthetase. Arch Biochem Biophys. 2002 Jan 15;397(2):293-7.</citation>
    <PMID>11795885</PMID>
  </reference>
  <reference>
    <citation>Micromedex Healthcare Series (http://wwwmicromed.mayo.edu).</citation>
  </reference>
  <reference>
    <citation>Berlow S, Bachman RP, Berry GT, Donnell GN, Grix A, Levitsky LL, Hoganson G, Levy HL. Betaine therapy in homocystinemia. Brain Dysfunct 2:10-24, 1989.</citation>
  </reference>
  <reference>
    <citation>Smolin LA, Benevenga NJ, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr. 1981 Sep;99(3):467-72.</citation>
    <PMID>7264811</PMID>
  </reference>
  <reference>
    <citation>Holme E, Kjellman B, Ronge E. Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency. Arch Dis Child. 1989 Jul;64(7):1061-4.</citation>
    <PMID>2629632</PMID>
  </reference>
  <reference>
    <citation>Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocystinuria--the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med. 1983 Aug 25;309(8):448-53.</citation>
    <PMID>6877313</PMID>
  </reference>
  <reference>
    <citation>Dudman NP, Guo XW, Gordon RB, Dawson PA, Wilcken DE. Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. J Nutr. 1996 Apr;126(4 Suppl):1295S-300S. doi: 10.1093/jn/126.suppl_4.1295S.</citation>
    <PMID>8642474</PMID>
  </reference>
  <reference>
    <citation>McGregor DO, Dellow WJ, Robson RA, Lever M, George PM, Chambers ST. Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. Kidney Int. 2002 Mar;61(3):1040-6.</citation>
    <PMID>11849459</PMID>
  </reference>
  <reference>
    <citation>van Guldener C, Janssen MJ, de Meer K, Donker AJ, Stehouwer CD. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. J Intern Med. 1999 Feb;245(2):175-83.</citation>
    <PMID>10081520</PMID>
  </reference>
  <reference>
    <citation>van Guldener C, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy. Clin Nephrol. 2000 Jan;53(1):33-41.</citation>
    <PMID>10661480</PMID>
  </reference>
  <reference>
    <citation>Matthews A, Johnson TN, Rostami-Hodjegan A, Chakrapani A, Wraith JE, Moat SJ, Bonham JR, Tucker GT. An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria. Br J Clin Pharmacol. 2002 Aug;54(2):140-6.</citation>
    <PMID>12207633</PMID>
  </reference>
  <reference>
    <citation>Surtees R, Bowron A, Leonard J. Cerebrospinal fluid and plasma total homocysteine and related metabolites in children with cystathionine beta-synthase deficiency: the effect of treatment. Pediatr Res. 1997 Nov;42(5):577-82.</citation>
    <PMID>9357926</PMID>
  </reference>
  <reference>
    <citation>Wendel U, Bremer HJ. Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr. 1984 Jun;142(2):147-50.</citation>
    <PMID>6381059</PMID>
  </reference>
  <reference>
    <citation>Devlin AM, Hajipour L, Gholkar A, Fernandes H, Ramesh V, Morris AA. Cerebral edema associated with betaine treatment in classical homocystinuria. J Pediatr. 2004 Apr;144(4):545-8.</citation>
    <PMID>15069409</PMID>
  </reference>
  <reference>
    <citation>Yaghmai R, Kashani AH, Geraghty MT, Okoh J, Pomper M, Tangerman A, Wagner C, Stabler SP, Allen RH, Mudd SH, Braverman N. Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency. Am J Med Genet. 2002 Feb 15;108(1):57-63.</citation>
    <PMID>11857551</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <results_first_submitted>November 1, 2012</results_first_submitted>
  <results_first_submitted_qc>November 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2013</results_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2013</last_update_posted>
  <responsible_party>
    <name_title>Dr. Carla G. Monico</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Primary Hyperoxaluria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from Mayo Clinic, Rochester between October 2006 and September 2008.</recruitment_details>
      <pre_assignment_details>Fifteen subjects were enrolled, but 2 subjects withdrew prior to group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Betaine First, Then Placebo</title>
          <description>Subjects received oral betaine 10 gm (subjects &gt;10 yrs old) or 6 gm (subjects &lt;10 yrs old) divided in two doses daily, for 2 months, followed by a 2 month washout period. Subjects then received oral lactose placebo divided in two doses daily, for 2 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Betaine</title>
          <description>Subjects received oral lactose placebo divided in two doses daily, for 2 months, followed by a 2 month washout period. Subjects then received oral betaine 10 gm (subjects &gt;10 yrs old) or 6 gm (subjects &lt;10 yrs old), divided in two doses daily, for 2 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 2 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive placebo first and betaine first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.1" lower_limit="6" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular Filtration Rate (GFR)</title>
          <units>ml/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79" lower_limit="39" upper_limit="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Subjects on Concomitant Medications</title>
          <description>Usual medications for primary hyperoxaluria were continued throughout the study. Subjects could have been prescribed more than one medication, so the sum of participants will be greater than the subject population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Vitamin B6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Citrate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Oxalate Excretion</title>
        <description>The patients were randomly assigned oral betaine or placebo for 2 months, followed by a 2 month washout. Each patient then received the alternate study medication for 2 months.
Urinary Oxalate Excretion was measured by oxalate oxidase. Two 24 hour urine collections were obtained at baseline, and during the eighth week of each study period.</description>
        <time_frame>baseline, 2 months, 6 months</time_frame>
        <population>Per protocol analysis: 10 of 15 enrolled PHI subjects completed the study: 2 withdrew before initiation, 2 were noncompliant, in 1 symptoms led to withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>Betaine</title>
            <description>Subjects received oral betaine 10 gm (subjects &gt;10 yrs old) or 6 gm (subjects &lt;10 yrs old), divided in two doses daily, for 2 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received oral lactose placebo divided in two doses daily, for 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Oxalate Excretion</title>
          <description>The patients were randomly assigned oral betaine or placebo for 2 months, followed by a 2 month washout. Each patient then received the alternate study medication for 2 months.
Urinary Oxalate Excretion was measured by oxalate oxidase. Two 24 hour urine collections were obtained at baseline, and during the eighth week of each study period.</description>
          <population>Per protocol analysis: 10 of 15 enrolled PHI subjects completed the study: 2 withdrew before initiation, 2 were noncompliant, in 1 symptoms led to withdrawal.</population>
          <units>umol/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.97"/>
                    <measurement group_id="O2" value="1.04" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects will be followed for adverse events for the 6 months while on study.</time_frame>
      <desc>Subjects unable to tolerate the initial dose due to gastrointestinal symptoms will be offered a dose reduction of 3 - 5 g/day. Monitoring for symptoms and signs of cerebral edema will be 1) weekly telephone calls from the study coordinator with a list of questions re: increased intracranial pressure and 2) full eye exam before and after treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Betaine</title>
          <description>Subjects received oral betaine 10 gm (subjects &gt;10 yrs old) or 6 gm (subjects &lt;10 yrs old), divided in two doses daily, for 2 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects received oral lactose placebo divided in two doses daily, for 2 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea/loose stools</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dawn S. Milliner</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-7431</phone>
      <email>milliner.dawn@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

